Bookbuilding IPO | ₹165 Cr | Listed at BSE, NSE | Fri, Feb 20, 2026 - Tue, Feb 24, 2026
Gaudium IVF IPO is a book build issue of ₹165.00 crores. The issue is a combination of fresh issue of 1.14 crore shares aggregating to ₹90.00 crores and offer for sale of 0.95 crore shares aggregating to ₹75.00 crores.
Gaudium IVF IPO bidding started from Feb 20, 2026 and ended on Feb 24, 2026. The allotment for Gaudium IVF IPO was finalized on Feb 25, 2026. The shares got listed on the NSE and the BSE on Feb 27, 2026.
Gaudium IVF IPO is set final issue price at ₹79 per share. The lot size for an application is 189 shares. The minimum amount of investment required by an individual investor (retail) is ₹14,931 (189 shares) (based on upper price). The lot size investment for sNII is 14 lots (2,646 shares), amounting to ₹2,09,034, and for bNII, it is 67 lots (12,663 shares), amounting to ₹10,00,377.
Sarthi Capital Advisors Pvt.Ltd. is the book running lead manager and Bigshare Services Pvt.Ltd. is the registrar of the issue.
Refer to Gaudium IVF IPO RHP for detailed Information.
IPO Open
Fri, Feb 20, 2026
IPO Close
Tue, Feb 24, 2026
Issue Price
₹79 per share
Market Cap (Pre-IPO)
₹575.02 Cr
| IPO Date | 20 to 24 Feb, 2026 |
| Listed on | Fri, Feb 27, 2026 |
| Face Value | ₹5 per share |
| Price Band | ₹75 to ₹79 |
| Issue Price | ₹79 per share |
| Lot Size | 189 Shares |
| Sale Type | Fresh capital cum OFS |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Total Issue Size | 2,08,86,200 shares (agg. up to ₹165 Cr) |
| Fresh Issue | 1,13,92,500 shares (agg. up to ₹90 Cr) |
| Offer for Sale | 94,93,700 shares of ₹5 (agg. up to ₹75 Cr) |
| Share Holding Pre Issue | 6,13,94,384 shares |
| Share Holding Post Issue | 7,27,86,884 shares |
| BSE Script Code / NSE Symbol | 544709 / GAUDIUMIVF |
| ISIN | INE0P8B01020 |
Gaudium IVF IPO offers total 2,08,86,200 shares. Out of which 1,04,43,100 (50.00%) allocated to QIB, 41,77,240 (20.00%) allocated to QIB (Ex- Anchor), 31,32,930 (15.00%) allocated to NII 73,10,170 (35.00%) allocated to RII and 62,65,860 (30.00%) allocated to Anchor investors.
| Investor Category | Shares Offered | Max Allottees |
|---|---|---|
| QIB Shares Offered | 1,04,43,100 (50.00%) | NA |
| − Anchor Investor Shares Offered | 62,65,860 (30.00%) | NA |
| − QIB (Ex. Anchor) Shares Offered | 41,77,240 (20.00%) | NA |
| NII (HNI) Shares Offered | 31,32,930 (15.00%) | NA |
| − bNII > ₹10L | 20,88,620 (10.00%) | 789 |
| − sNII < ₹10L | 10,44,310 (5.00%) | 394 |
| Retail Shares Offered | 73,10,170 (35.00%) | 38,678 |
| Total Shares Offered | 2,08,86,200 (100.00%) |
Investors can bid for a minimum of 189 shares and in multiples thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 189 | ₹14,931 |
| Retail (Max) | 13 | 2,457 | ₹1,94,103 |
| S-HNI (Min) | 14 | 2,646 | ₹2,09,034 |
| S-HNI (Max) | 66 | 12,474 | ₹9,85,446 |
| B-HNI (Min) | 67 | 12,663 | ₹10,00,377 |
Gaudium IVF IPO raises ₹49.50 crore from anchor investors. Gaudium IVF IPO Anchor bid date is February 19, 2026.
📝 Anchor Investors Letter (PDF)
| Bid Date | Thu, Feb 19, 2026 |
| Shares Offered | 62,65,860 |
| Anchor Portion (₹ Cr.) | 49.50 |
| Anchor lock-in period end date for 50% shares (30 Days) | Thu, Mar 26, 2026 |
| Anchor lock-in period end date for remaining shares (90 Days) | Mon, May 25, 2026 |
Incorporated in March 2015, Gaudium IVF and Women Health Limited have engaged in In Vitro Fertilization (IVF) treatments throughout India and have expanded into several states utilizing a hub-and-spoke model.
The company operates over thirty locations, which include seven hubs (centres) and twenty-eight spokes. The organization has entered into a strategic alliance with Infertility Experts, known as Spokes, to achieve the mutual objective of raising awareness regarding Assisted Reproductive Technology (ART) and In Vitro Fertilization (IVF) treatments.
The company serves patients from various countries, including Canada, the United Kingdom, the United States, Kenya, South Africa, and Oman.
The company has centres in major cities: two in Delhi (Janakpuri, Kailash Colony), and one each in Mumbai (Khar West), Ludhiana, Srinagar, Patna, and Bangalore, covering key locations across India.
The company offers specialized fertility services, including In Vitro Fertilization (IVF), Intracytoplasmic Sperm Injection (ICSI), Intrauterine Insemination (IUI), and ovulation induction. The company's treatments are designed for various infertility challenges for both genders. The company also provide comprehensive gynaecological care for PCOD/PCOS and endometriosis, as well as high-risk pregnancy management for women with complex fertility histories or health conditions.
| Period Ended | 30 Sep 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 106.62 | 88.51 | 51.01 | 36.63 |
| Total Income | 49.75 | 70.96 | 48.15 | 44.26 |
| Profit After Tax | 12.51 | 19.13 | 10.32 | 13.53 |
| EBITDA | 18.95 | 28.63 | 19.27 | 20.07 |
| NET Worth | 58.85 | 46.30 | 26.99 | 22.73 |
| Reserves and Surplus | 28.16 | 15.60 | 26.00 | 21.74 |
| Total Borrowing | 22.51 | 18.93 | 15.73 | 9.78 |
| Amount in ₹ Crore | ||||
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Funding capital expenditure towards establishment of New IVF Centers of the Company. | 50.00 |
| 2 | Repayment/pre-payment, in full or in part, of certain outstanding loans availed by the Company. | 20.00 |
| 3 | General Corporate Purpose | 12.28 |
| Total | 82.28 |
| KPI | Sep 30, 2025 | Mar 31, 2025 |
|---|---|---|
| ROE | 21.25% | 41.31% |
| ROCE | 21.03% | 39.70% |
| Debt/Equity | 0.38 | 0.41 |
| RoNW | 21.34% | 41.71% |
| PAT Margin | 25.14% | 26.96% |
| EBITDA Margin | 38.29% | 40.48% |
| Price to Book Value | 10.48 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (₹) | 3.12 | 3.44 |
| P/E (x) | 25.36 | 22.99 |
| Promoter Holding | 99.99% | 71.30% |
| Market Cap | ₹575.02 Cr. |
The Gaudium IVF IPO is subscribed 7.27 times on February 24, 2026 6:54:51 PM (Day 3). The public issue subscribed 7.60 times in the retail category, 1.62 times in the QIB category, and 14.05 times in the NII category. Check Day by Day Subscription Details (Live Status)
| Category | Subscription (x) | Shares Offered | Shares bid for |
|---|---|---|---|
| QIB (Ex Anchor) | 1.62 | 41,77,240 | 67,85,478 |
| NII | 14.05 | 31,32,930 | 4,40,22,069 |
| bNII (> ₹10L) | 12.71 | 20,88,620 | 2,65,55,634 |
| sNII (< ₹10L) | 16.73 | 10,44,310 | 1,74,66,435 |
| Retail | 7.60 | 73,10,170 | 5,55,42,942 |
| Total | 7.27 | 1,46,20,340 | 10,63,50,489 |
Total Applications: 2,49,109
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Fees payable to the BRLM (including underwriting commission) | 9.25 |
| 2 | Advertising and marketing expenses | 1.10 |
| 3 | Fees to the Registrar to the Offer | 0.25 |
| 4 | Fees payable to the Regulators including stock exchanges | 1.45 |
| 5 | Printing and distribution of Issue stationary | 0.30 |
| 6 | Commission/processing fee for SCSBs, Sponsor Bank (for Bids made by Retail Individual Bidders using UPI) and Bankers to the Offer. Brokerage, underwriting commission and selling commission and bidding charges for Members of the Syndicate, Registered Brokers, RTAs and CDPs | 0.70 |
| 7 | Fees for the legal counsels appointed for the purpose of the Offer | 0.35 |
| 8 | Others (Industry Report, charges for monitoring Agency, Restated financials, NSDL & CDSL Fees, Verification Charges etc.) | 0.75 |
| Total | 14.15 |
| Price Details | BSE | NSE |
|---|---|---|
| Final Issue Price | ₹79.00 | ₹79.00 |
| Open | ₹83.00 | ₹83.00 |
| Low | ₹79.05 | ₹79.50 |
| High | ₹87.15 | ₹87.15 |
| Last Trade | ₹80.48 | ₹80.26 |
Lead Manager Reports
Gaudium IVF IPO is a main-board IPO of 2,08,86,200 equity shares of the face value of ₹5 aggregating up to ₹165 Crores. The issue is priced at ₹79 per share. The minimum order quantity is 189.
The IPO opens on Fri, Feb 20, 2026, and closes on Tue, Feb 24, 2026.
Bigshare Services Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Gaudium IVF IPO using UPI as a payment gateway. Zerodha customers can apply in Gaudium IVF IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Gaudium IVF IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Gaudium IVF IPO opens on Fri, Feb 20, 2026 and closes on Tue, Feb 24, 2026.
Gaudium IVF IPO lot size is 189, and the minimum amount required for application is ₹14,931.
You can apply in Gaudium IVF IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Gaudium IVF IPO will be done on Wednesday, February 25, 2026, and the allotted shares will be credited to your demat account by Thu, Feb 26, 2026. Check the Gaudium IVF IPO allotment status.
The Gaudium IVF IPO listing date is on Fri, Feb 27, 2026.
